Stocks · News reference
Vivos Therapeutics To Acquire 11% Stake In SOD Sciences And A 50% Interest In SOD’s Proprietary Pseudohypoxia Early-Warning Test For 12K Shares Of Newly Created Convertible Prefs Worth $12M
Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Vivos Therapeutics, Inc. (VVOS)
Filed: 2026-10-21 AccNo: 0001493152-26-047841 Size: 226 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Why 3M Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
3M shares rose 4.4% premarket after expanding its Amazon data-center deal, including a $521.4M stock warrant; other stocks saw sharp moves.
Vivos Therapeutics Closes Its Acquisition Of An 11% Fully Diluted Equity Interest In Sod Sciences And A 50% Undivided Co-Ownership Interest In SOD's Pseudohypoxia Early‑Warning Test, The "Primed Cell For Chronic Disease" Test; Vivos Issued To SOD 12,000 Shares Of Newly Created Series C Convertible Preferred Stock With An Aggregate Stated Value Of $12M
Vivos Therapeutics, Inc. (NASDAQ:VVOS) ("Vivos" or the "Company") today announced that it has closed its acquisition of an 11% fully diluted equity interest in SOD Sciences, Inc. ("SOD Sciences"